从治疗到治愈：我国乙肝防治迈入临床治愈新时代

Core Insights - The article discusses the launch of the "Hepatitis B Prevention and Health Education Project" and the "Action Plan for the Prevention and Control of Viral Hepatitis in China (2025-2030)" aimed at addressing the significant public health challenge posed by viral hepatitis, particularly Hepatitis B in China [1][2] Group 1: Current Situation and Challenges - Viral hepatitis is a major public health challenge globally, with Hepatitis B being the most prevalent and burdensome type in China [1] - Approximately 75 million people in China are chronic Hepatitis B virus carriers, with around 30 million unaware of their infection status, and only about 3 million of the 17 million needing treatment receiving standardized care [1][2] Group 2: Action Plan and Goals - The "Action Plan" aims to improve diagnosis and treatment rates, control new infections, and reduce the incidence and mortality of liver cirrhosis and liver cancer, laying the groundwork for the eventual elimination of viral hepatitis as a public health threat [2] - The plan encourages increased innovation in drug development and exploration of clinical pathways for functional cure of Hepatitis B [2] Group 3: Advances in Treatment - The treatment goals for chronic Hepatitis B in China have evolved from "disease control" to pursuing "clinical cure," with new drug trials emphasizing this shift [3] - The approval of pegylated interferon α-2b in 2025 for the sustained clearance of Hepatitis B surface antigen marks a significant upgrade in treatment objectives [3] Group 4: Implementation and Outreach - The establishment of nearly 1,300 "Hepatitis B Clinical Cure Clinics" promotes a patient-centered management system, enhancing the accessibility of advanced treatment outcomes [4] - The "Hepatitis B Knowledge" project aims to improve public understanding of Hepatitis B through educational activities, collaboration among institutions, and patient education, ultimately reducing the incidence and burden of the disease [4]